Skip to main content
Log in

Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs

  • Calcium Antagonists
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

In the present study we investigated the relationship between pharmacodynamic and pharmacokinetic properties of the benzothiazepine-like calcium antagonists, clentiazem and diltiazem. Experiments were carried out in closed-chest anesthetized dogs, instrumented for hemodynamic recording and blood sampling. Clentiazem and diltiazem bolus injections (400 µg/kg) were administered intravenously, and subgroups of animals were sacrificed at 15, 30, 60, or 120 minutes Clentiazem and diltiazem plasma and myocardial levels were determined by high performance liquid chromatography (HPLC). Clentiazem elicited a more marked reduction in mean arterial pressure (−17% for clentiazem vs. −12% for diltiazem), along with an attenuation of the expected positive reflex chronotropic response. Pharmacokinetic analysis revealed that clentiazem had a greater volume of distribution (33±16 l vs. 15±9 l for diltiazem), while the half-life of elimination (t1/2β) was similar (55±21 minutes vs. 59±23 minutes). The kinetic disposition profile of both drugs was analyzed through myocardial/plasma concentration ratios. In the distribution phase (0–15 minutes), this ratio was similar (26±2 for clentiazem vs. 18±5 diltiazem), suggesting that the myocardium was not a preferential site of distribution for either drugs. Data collected within the elimination phase indicate significant myocardial retention for clentiazem; at the end of the study period, the myocardial/plasma concentration ratio was twofold higher for clentiazem. The observed retention of clentiazem in the myocardium may be responsible for attenuation of the baroreflex. Clentiazem increased potency was confirmed by the fact that its hypotensive and cardioinhibitory effects were observed at lower plasma concentrations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Petru MA, Crawford MH, Sorensen SG, et al. Short- and long-term efficacy of high-dose oral diltiazem for angina due to coronary artery disease: A placebo-controlled, randomized, double-blind crossover study.Circulation 1983;68:139–147.

    Google Scholar 

  2. Pool PE, Massie BM, Venkataraman K, et al. Diltiazem as monotherapy for systemic hypertension: A multicenter, randomized, placebo-controlled trial.Am J Cardiol 1986;57:212–217.

    Google Scholar 

  3. Dias VC, Plumb VJ. Intravenous diltiazem in patients with atrial fibrillation/atrial flutter.Drug Invest 1991;3:8–13.

    Google Scholar 

  4. Sato M, Nagao T, Yamaguchi I, et al. Pharmacological studies on a new 1,5-benzothiazepine derivative (CRD-401). I. Cardiovascular actions.Arzneim-Forsch 1971;21:1338–1343.

    Google Scholar 

  5. Nagao T, Sato M, Nakajima H, et al. Studies on a new 1,5-benzothiazepine derivative (CRD-401). II. Vasodilator actions.Jpn J Pharmacol 1972;22:1–10.

    Google Scholar 

  6. Narita H, Murata S, Yabana H, et al. Long-lasting hypotensive and antihypertensive effects of a new 1,5-benzothiazepine calcium antagonist in hypertensive rats and renal hypertensive dogs.Arzneim-Forsch 1988;38:515–520.

    Google Scholar 

  7. Narita H, Ginsburg R. In-vitro study of the effect of clentiazem on rabbit aorta and on myocardium.Cardiovasc Drugs Ther 1990;4:723–730.

    Google Scholar 

  8. Nakamura S, Ohashi M, Suzuki T, et al. Metabolic fate of the new Ca2+-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate: Distribution, excretion and protein binding in rats and dogs.Arzneim-Forsch 1989;39:1100–1108.

    Google Scholar 

  9. Villiere V, Dumont L, Lefebvre M, et al. Relationship between cardiovascular effects, plasma and myocardial levels of clentiazem, a new benzothiazepine calcium antagonist, in anesthetized dogs.Cardiovasc Drugs Ther 1991;5:997–1003.

    Google Scholar 

  10. Dumont L, Archambault P, Giasson S, et al. Inotropic and chronotropic properties of benzothiazepine-like calcium antagonists.FASEB J 1991;5:A874.

    Google Scholar 

  11. Lefebvre M, Garceau D, Spenard J, et al. High performance liquid chromatographic method for the assay of TA-3090 and its pharmacokinetic parameters in healthy volunteers.J Pharm Biomed Anal 1989;7:1919–1924.

    Google Scholar 

  12. Boucher S, Varin F, Theoret Y, et al. High-performance liquid chromatographic method for the determination of diltiazem and two of its metabolites in human plasma: Application to a new sustained release formulation.J Pharm Biomed Anal 1989;7:1925–1930.

    Google Scholar 

  13. Kikkawa K, Murata S, Nagao T. Calcium antagonistic and spasmolytic activities of a new 1,5-benzothiazepine derivative in isolated canine and monkey arteries.Arzneim-Forsch 1988;38:526–531.

    Google Scholar 

  14. Isshiki T, Pegram BL, Frohlich ED. Hemodynamic comparison of diltiazem and TA-3090 in spontaneously hypertensive and normal Wistar-Kyoto rats.Am J Cardiol 1988;62:79G-84G.

    Google Scholar 

  15. Isshiki T, Pegram BL, Frohlich ED. Immediate and prolonged hemodynamic effects of TA-3090 on spontaneously hypertensive (SHR) and normal Wistar-Kyoto (WKY) rats.Cardiovasc Drug Ther 1988;2:539–547.

    Google Scholar 

  16. Murata S, Kikkawa K, Yabana H, Nagao T. Cardiovascular effects of a new 1,5-benzothiazepine calcium antagonist in anesthetized dogs.Arzneim-Forsch 1988;38:521–525.

    Google Scholar 

  17. Dumont L, Derouin C, Chartrand C, et al. Peripheral vasodilator and cardiac properties of the 1,5-benzothiazepine calcium antagonist analog, TA-3090, in dogs.Can J Physiol Pharmacol 1991;69:512–517.

    Google Scholar 

  18. Narita H, Zera PH, Ginsburg R. Mechanism of action of clentiazem on human coronary artery and myocardium.Cardiovasc Drug Ther 1990;4:1097–1104.

    Google Scholar 

  19. Rigel DF, Millard RW. Effects of calcium channel antagonists on carotid sinus baroreflex control of arterial pressure and heart rate in anesthetized dogs.Circ Res 1989;64:276–286.

    Google Scholar 

  20. Giudicelli JF, Berdeaux A, Edouard A, et al. Attenuation by diltiazem of arterial baroreflex sensitivity in man.Eur J Clin Pharmacol 1984;26:675–679.

    Google Scholar 

  21. Zsoter TT, Nebitko RL, Chow R. The effect of verapamil, diltiazem and nifedipine on baroreceptor reflexes.Clin Invest Med 1988;11:430–434.

    Google Scholar 

  22. Ingenito AJ, Abdel-Rahman A-RA. Differences between calcium channel blockers in effects on arterial baroreflexes.Pharmacologist 1983;25:146.

    Google Scholar 

  23. Heesch CM, Miller BM, Thames MD, et al. Effects of calcium channel blockers on isolated carotid baroreceptors and baroreflex.Am J Physiol 1983;245:H653-H661

    Google Scholar 

  24. Kunze DL, Andresen MC, Torres LA. Do calcium antagonists act directly on calcium channels to alter baroreceptor function?Am Soc Pharmacol Exp Ther 1986;239:303–310.

    Google Scholar 

  25. Nakamura S, Suzuki T, Sugawara Y, et al. Metabolic fate of diltiazem (distribution, excretion and protein binding in rat and dog).Arzneim-Forsch 1987;37:1244–1252.

    Google Scholar 

  26. Hermann P, Morselli PL. Pharmacokinetics and electrophysiologic effects of diltiazem.Acta Pharmacol Toxicol 1985;57(Suppl 1–3):10–20.

    Google Scholar 

  27. Legrand V, Hastir F, Vandormael M, et al. Haemodynamic effects of intravenous diltiazem at rest and exercise in patients with coronary artery disease.Eur Heart J 1984;5:456–463.

    Google Scholar 

  28. Browne RK, Dimmitt DC, Miller LD, et al. Relationship between plasma diltiazem and cardiovascular responses in conscious dogs.J Cardiovasc Pharmacol 1983;5:483–490.

    Google Scholar 

  29. Fujimoto Y, Peter T, Mandel WJ. Electrophysiologic and hemodynamic actions of diltiazem: Disparate temporal effects shown by experimental dose-response studies.Am Heart J 1981;101:403–407.

    Google Scholar 

  30. Smith MS, Verghese CP, Shand DG, et al. Pharmacokinetic and pharmacodynamic effects of diltiazem.Am J Cardiol 1983;51:1369–1374.

    Google Scholar 

  31. Taeymans Y, Clozel JP, Caille G, et al. Relationship between diltiazem plasma levels and its hemodynamic effects.Circulation 1982;66:II81.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giasson, S., Garceau, D., Homsy, W. et al. Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs. Cardiovasc Drug Ther 9, 685–692 (1995). https://doi.org/10.1007/BF00878551

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00878551

Key Words

Navigation